OptumRx Inc. chief formulary and procurement officer Kent Rogers, Cigna Corp. chief clinical officer Steve Miller and Harvard-Pilgrim Health Care chief medical officer Michael Sherman offered their perspectives on reimbursement for high-cost therapies, both chronic and curative, at the Biotechnology Innovation Organization virtual international convention. They were joined by Jason Tardio, chief commercial officer for Ovid Therapeutics Inc., which is developing treatments for rare disease.
The panel discussion, moderated by Real Endpoints CEO Jeff Berkowitz, focused on pharmacy benefit manager and payer concerns with affordability,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?